Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

NCT01123304 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped This study has been terminated due to lack of availability of investigational product.

Conditions

Melanoma

Interventions

DRUG: MORAb028

Sponsor

Morphotek